Abid Hussain

Research Associate Future Industries Institute

Mawson Lakes Campus ()
tel +61 8 830 23929

email Abid.Hussain@unisa.edu.au

Alternative contact

Research Degree Supervisor

About me

mRNA therapeutics, siRNA therapeutics, LNPs

Dr Abid Hussain is an emerging research leader in drug delivery and RNA therapeutics, with a Ph.D. in Pharmaceutical Sciences (2019) and a strong track record spanning both industry and academia. His expertise lies in the design and development of lipid-based nanoparticles for targeted delivery of mRNA and siRNA to treat cancer, cardiovascular, respiratory viral infection and metabolic diseases.

As a former Formulation Manager in a leading pharmaceutical company (2019-2021), Dr Hussain led multiple inhalation-based formulation projects, contributing to three internationally patented technologies (WIPO/PCT) and playing a pivotal role in the successful submission of two drug products to the European Medicines Agency (EMA) between... Read more

Future Industries Institute

The Institute partners with today’s industries, to create the industries of tomorrow.

Tweets by @UniversitySA

About me

After transitioning back to academia in 2021, Dr Hussain has made significant contribution to the field of drug delivery technologies, with a more specific recent focus on mRNA therapeutics. As an early career researcher, he has published 29 peer-reviewed articles including in Nature Communications (IF 14.7), Science Advances (IF 14.0), Signal Transduction and Targeted Therapy (IF 40.8), Bioactive Materials (IF 18), Journal of Controlled Release (IF 10.5), Nano Letters (IF 9.6), Plos Pathogen (IF 5.5), Biomaterials Science (5.8), Nano Research (IF 9.6), Molecular Therapy (IF 12.1), and Journal of Nanobiotechnology (10.6). His publications have received over 1240 citations and h-index is 19 (i10-index of 26) (accumulated IF of 250+).

A recent highlight is his recent first authorship publication in Nature Communication (2024) reporting the development of a lipid-based formulation for the delivery of mRNA for the treatment of Hyperuricemia and Gout. This work has significant translational potential and underscores the transformative potential of mRNA therapeutics in addressing metabolic disorders.

His experience working in multidisciplinary teams ideally positions him to contribute significant advances in the RNA therapeutic field. Under the mentoring of Prof Thierry and in collaboration with experts in heart failure (Baker Inst), pancreatic cancer (Garvan Inst) and lung disease (University of Adelaide), Dr Hussain currently leads an innovative research program on targeted lipid nanoparticles for organ-specific RNA delivery, offering possible treatments for cardiovascular diseases, cancer and respiratory viral infection.

About me

Experience

Qualifications

Doctor of Philosophy Shanghai Jiao Tong University
Doctor of Pharmacy Gomal University
Master of Philosophy University of Malakand

Work history

Dr Abid Hussain is an early-career research leader in drug delivery and RNA therapeutics, with expertise in lipid nanoparticle (LNP)-based delivery systems for mRNA and siRNA targeting cancer, cardiovascular, respiratory, and metabolic diseases. He holds a Ph.D. in Pharmaceutical Sciences (2019) and brings a unique blend of industrial and academic experience to his research.

From 2019 to 2021, Dr Hussain served as Formulation Manager in a leading pharmaceutical company, where he led inhalation-based drug delivery projects, contributed to three WIPO-registered patents, and played a key role in submitting two products to the European Medicines Agency (EMA).

Since returning to academia in 2021, he has published 29 peer-reviewed articles in top-tier journals including Nature Communications, Science Advances, Signal Transduction and Targeted Therapy, Molecular Therapy, and Journal of Controlled Release, accumulating over 1240 citations and an h-index of 19. His recent Nature Communications study demonstrated a novel ionizable lipid-based LNP formulation for delivering mRNA to treat hyperuricemia and gout, underscoring the clinical potential of RNA therapeutics for metabolic diseases.

Currently based at the Future Industries Institute, UniSA, Dr Hussain leads research on ligand-conjugated LNPs for targeted RNA delivery. Working under the mentorship of Prof Thierry and in collaboration with experts at the Baker Heart & Diabetes Institute, Garvan Institute, and McCarron Lab, he is advancing preclinical mRNA-based therapies for heart failure, pancreatic cancer, and viral respiratory infections.

Research

Research focus

Biomedical Engineering
Biochemistry and Cell Biology
Chemical Sciences
Pharmacology and Pharmaceutical Sciences
Technology

Highlights

Leading projects on optimizing and developing ligand conjugated LNPs for delivery functional mRNA for the treatment of Pancreatic Cancer, Heart Failure by collaborating with Baker Institute and Garvin Institute experts.

Strong collaboration with Cystic Fibrosis Research Group at the University of Adelaide, Dr Hussain is working to develop ligand Conjugated LNPs specifically for pulmonary delivery.

Research

Outputs

Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus

Open access indicates that an output is open access.

Highlights

Year	Output
2024	Zhang, M, Hussain, A, Hu, B, Yang, H, Li, C, Guo, S, Han, X, Li, B, Dai, Y, Cao, Y, Chi, H, Weng, Y, Qin, C-F & Huang, Y 2024, 'Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA', Nature Communications, vol.15, no. 1, pp. 1-16. Open access 11 10
2023	Zhang, M, Hussain, A, Yang, H, Zhang, J, Liang, XJ & Huang, Y 2023, 'mRNA-based modalities for infectious disease management', Nano Research, vol. 16, no. 1, pp. 672-691. 18 18 20
2022	Hu, B, Hussain, A, Liu, Q, Weng, Y & Huang, Y 2022, 'Advances in mRNA delivery and clinical applications', in Stefan Jurga & Jan Barciszewski (eds), Messenger RNA Therapeutics, Springer, Switzerland, ch. 13, pp. 277-305. 1
2022	Hu, B, Li, B, Li, K, Liu, Y, Li, C, Zheng, L, Zhang, M, Yang, T, Guo, S, Dong, X, Zhang, T, Liu, Q, Hussain, A, Weng, Y, Peng, L, Zhao, Y, Liang, XJ & Huang, Y 2022, 'Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia', Science Advances, vol. 8, no. 7, article no. eabm1418, pp. 1-18. Open access 70 70 3
2022	Hussain, A, Yang, H, Zhang, M, Liu, Q, Alotaibi, G, Irfan, M, He, H, Chang, J, Liang, XJ, Weng, Y & Huang, Y 2022, 'mRNA vaccines for COVID-19 and diverse diseases', Journal of Controlled Release, vol. 345, pp. 314-333. 91 74 12

Chapters

Year	Output
2022	Hu, B, Hussain, A, Liu, Q, Weng, Y & Huang, Y 2022, 'Advances in mRNA delivery and clinical applications', in Stefan Jurga & Jan Barciszewski (eds), Messenger RNA Therapeutics, Springer, Switzerland, ch. 13, pp. 277-305. 1
2022	Hussain, A, Weng, Y & Huang, Y 2022, 'Graphene and graphene-based nanomaterials: current applications and future perspectives', in Yasser Shahzad et al. (eds), Drug Delivery Using Nanomaterials, CRC Press, US, ch. 9, pp. 209-228. 5
2022	Sohail, M, Rabbi, F, Younas, A, Hussain, A, Yu, B, Li, Y, Iqbal, S, Ullah, KH, Qadeer, A, Aquib, M, Iqbal, H & Xu, H 2022, 'Herbal bioactive-based nano drug delivery systems', in IS Bakshi, R Bala & RK Sindhu (eds), Herbal Bioactive-Based Drug Delivery Systems: Challenges and Opportunities, Elsevier, UK, ch. 6, pp. 169-193. 7

Journal Articles

Year	Output
2024	Zhang, M, Hussain, A, Hu, B, Yang, H, Li, C, Guo, S, Han, X, Li, B, Dai, Y, Cao, Y, Chi, H, Weng, Y, Qin, C-F & Huang, Y 2024, 'Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA', Nature Communications, vol.15, no. 1, pp. 1-16. Open access 11 10
2023	Hu, B, Kong, S, Weng, Y, Zhao, D, Hussain, A, Jiao, Q, Zhan, S, Qiu, L, Lin, J, Xie, M, Li, B & Huang, Y 2023, 'Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy', Chinese Chemical Letters, vol. 34, no. 11, article no. 108210, pp. 1-7. 10 11 4
2023	Zhang, M, Hussain, A, Yang, H, Zhang, J, Liang, XJ & Huang, Y 2023, 'mRNA-based modalities for infectious disease management', Nano Research, vol. 16, no. 1, pp. 672-691. 18 18 20
2022	Hu, B, Li, B, Li, K, Liu, Y, Li, C, Zheng, L, Zhang, M, Yang, T, Guo, S, Dong, X, Zhang, T, Liu, Q, Hussain, A, Weng, Y, Peng, L, Zhao, Y, Liang, XJ & Huang, Y 2022, 'Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia', Science Advances, vol. 8, no. 7, article no. eabm1418, pp. 1-18. Open access 70 70 3
2022	Hussain, A, Yang, H, Zhang, M, Liu, Q, Alotaibi, G, Irfan, M, He, H, Chang, J, Liang, XJ, Weng, Y & Huang, Y 2022, 'mRNA vaccines for COVID-19 and diverse diseases', Journal of Controlled Release, vol. 345, pp. 314-333. 91 74 12
2022	Irfan, M, Shahid, AL, Ahmad, M, Iqbal, W, Elavarasan, RM, Ren, S & Hussain, A 2022, 'Assessment of public intention to get vaccination against COVID-19: Evidence from a developing country', Journal of Evaluation in Clinical Practice, vol. 28, no. 1, pp. 63-73. 55 58 8
2022	Li, C, Yang, T, Weng, Y, Zhang, M, Zhao, D, Guo, S, Hu, B, Shao, W, Wang, X, Hussain, A, Liang, XJ & Huang, Y 2022, 'Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy', Bioactive Materials, vol. 9, pp. 590-601. Open access 61 56 4
2022	Tuguntaev, RG, Hussain, A, Fu, C, Chen, H, Tao, Y, Huang, Y, Liu, L, Liang, XJ & Guo, W 2022, 'Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations', Journal of Nanobiotechnology, vol. 20, no. 1, article no. 236, pp. 1-31. Open access 19 15
2022	Ullah, A, Chen, G, Yibang, Z, Hussain, A, Shafiq, M, Raza, F, Liu, D, Wang, K, Cao, J & Qi, X 2022, 'A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis', Biomaterials Science, vol. 10, no. 10, pp. 2650-26644. 15 13 1
2022	Xu, M, Mao, C, Chen, H, Liu, L, Wang, Y, Hussain, A, Li, S, Zhang, X, Tuguntaev, RG, Liang, XJ, Guo, W & Cao, F 2022, 'Osteopontin targeted theranostic nanoprobes for laser-induced synergistic regression of vulnerable atherosclerotic plaques', Acta Pharmaceutica Sinica B, vol. 12, no. 4, pp. 2014-2028. Open access 21 18 1
2022	Yu, C, Li, K, Xu, L, Li, B, Li, C, Guo, S, Li, Z, Zhang, Y, Hussain, A, Tan, H, Zhang, M, Zhao, Y, Huang, Y & Liang, XJ 2022, 'siRNA-functionalized lanthanide nanoparticle enables efficient endosomal escape and cancer treatment', Nano Research, vol. 25, no. 10, pp. 9160-9168. 14 14 11
2021	Guo, S, Li, K, Hu, B, Li, C, Zhang, M, Hussain, A, Wang, X, Cheng, Q, Yang, F, Ge, K, Zhang, J, Chang, J, Liang, XJ, Weng, Y & Huang, Y 2021, 'Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment', Exploration, vol. 1, no. 1, pp. 35-49. Open access 143
2021	Li, C, Zhou, J, Wu, Y, Dong, Y, Du, L, Yang, T, Wang, Y, Guo, S, Zhang, M, Hussain, A, Xiao, H, Weng, Y, Huang, Y, Wang, X, Liang, Z, Cao, H, Zhao, Y, Liang, XJ, Dong, A & Huang, Y 2021, 'Core role of hydrophobic core of polymeric nanomicelle in edosomal escape of siRNA', Nano Letters: A Journal Dedicated to Nanoscience and Nanotechnology, vol. 21, no. 8, pp. 3680-3689. 84 84
2021	Li, K, Zhang, Y, Hussain, A, Weng, Y & Huang, Y 2021, 'Progress of photodynamic and RNAi combination therapy in cancer treatment', ACS Biomaterial Science and Engineering, vol. 7, no. 9, pp. 44200-4429. 22 21 3
2021	Ullah, A, Chen, G, Hussain, A, Khan, H, Abbas, A, Zhou, Z, Shafiq, M, Ahmad, S, Ali, U, Usman, M, Raza, F, Ahmed, A, Qiu, Z, Zheng, M & Liu, D 2021, 'Cyclam-modified polyethyleneimine for simultaneous tgfβ sirna delivery and cxcr4 inhibition for the treatment of ccl₄ induced liver fibrosis', International Journal of Nanomedicine, vol. 16, pp. 4451-4470. Open access 17 16 2
2019	Hussain, A & Guo, S 2019, 'NIR-triggered release of DOX from sophorolipid-coated mesoporous carbon nanoparticles with the phase-change material 1-tetradecanol to treat MCF-7/ADR cells', Journal of Materials Chemistry B, vol. 7, no. 6, pp. 974-985. 26 25 1
2019	Khan, MT, Junaid, M, Mao, X, Wang, Y, Hussain, A, Malik, SI & Wei, DQ 2019, 'Pyrazinamide resistance and mutations L19R, R140H, and E144K in Pyrazinamidase of Mycobacterium tuberculosis', Journal of Cellular Biochemistry, vol. 120, no. 5, pp. 7154-7166. 16 15 1
2017	Huang, S, Liu, J, Zhu, H, Hussain, A, Liu, Q, Li, J, Shen, Y, Cheng, J & Guo, S 2017, 'PEGylated doxorubicin micelles loaded with curcumin exerting synergic effects on multidrug resistant tumor cells', Journal of Nanoscience and Nanotechnology, vol. 17, no. 5, pp. 2873-2880. 14 13
2017	Zhang, Z, Wang, Y, Xu, S, Yu, Y, Hussain, A, Shen, Y & Guo, S 2017, 'Photothermal gold nanocages filled with temperature sensitive tetradecanol and encapsulated with glutathione responsive polycurcumin for controlled DOX delivery to maximize anti-MDR tumor effects', Journal of Materials Chemistry B, vol. 5, no. 27, pp. 5464-5472. 31 29 1
2017	Zhu, H, Wang, Y, Hussain, A, Zhang, Z, Shen, Y & Guo, S 2017, 'Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells', Journal of Materials Chemistry B, vol. 5, no. 19, pp. 3531-3540. 32 25 6
2016	Ullah, F, Ayaz, M, Sadiq, A, Hussain, A, Ahmad, S, Imran, M & Zeb, A 2016, 'Phenolic, flavonoid contents, anticholinesterase and antioxidant evaluation of Iris germanica var; florentina', Natural Product Research, vol. 30, no. 12, pp. 1440-1444. 75 64 3

Other outputs

GoogleScholar Profile: https://scholar.google.com.au/citations?user=BSLQWlcAAAAJ&hl=en

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Abasyn University	PAKISTAN
Affiliated Hospital of Nantong University	CHINA
Aix-Marseille University	FRANCE
Beijing Institute of Microbiology and Epidemiology	CHINA
Beijing Institute of Technology	CHINA
Capital University of Science and Technology	PAKISTAN
China Pharmaceutical University	CHINA
Chinese Academy of Sciences	CHINA
Chinese PLA General Hospital	CHINA
Guangxi Medical University	CHINA
Guangzhou Medical University	CHINA
Hebei University	CHINA
Henan Normal University	CHINA
Jiangnan University	CHINA
Jiangsu University	CHINA
Nankai University	CHINA
Nantong University	CHINA
National Center for Nanoscience and Technology of China	CHINA
Nestlives Private Limited	INDIA
Peking University	CHINA
Quaid-i-Azam University	PAKISTAN
Shandong University	CHINA
Shanghai Jiao Tong University	CHINA
Shanghai University	CHINA
Shanghai Veterinary Research Institute	CHINA
Shantou University	CHINA
Shantou University Medical College	CHINA
Shaqra University	SAUDI ARABIA
Shenzhen University	CHINA
Soochow University	TAIWAN
Tianjin Medical University	CHINA
Tianjin University	CHINA
University of California	UNITED STATES
University of Macau	MACAU (SAR OF CHINA)
University of Malakand	PAKISTAN
University of Texas Southwestern Medical Center	UNITED STATES
Women's and Children's Hospital	AUSTRALIA
Yangzhou University	CHINA
Yantai University	CHINA
Zhejiang University	CHINA
Zhengzhou University	CHINA

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
111875-Turning foes into allies: Hijacking myofibroblasts to regenerate cardiac tissues with RNA therapeutics	Current

more less

Abid Hussain

Alternative contact

Alternative contact details

About me

About me

Future Industries Institute

About me

Professional Associations

Experience

Qualifications

Work history

Research

Research focus

Highlights

Projects

Outputs

Highlights

Chapters

Journal Articles

Other outputs

Current research & highlights

External engagement & recognition

Collaborations

Collaborations

Teaching & student supervision

Courses and programs

Research degree supervision

Gallery